Stockscreener 앱 받기
3.49
2.35%
0.08
시장 영업 전:
3.55
0.06
+1.72%
전일 마감가:
$3.41
열려 있는:
$3.47
하루 거래량:
1.62M
Relative Volume:
0.57
시가총액:
$942.27M
수익:
-
순이익/손실:
$-244.17M
주가수익비율:
-3.5747
EPS:
-0.9763
순현금흐름:
$-144.77M
1주 성능:
+4.18%
1개월 성능:
+9.06%
6개월 성능:
-14.46%
1년 성능:
+86.63%
1일 변동 폭
$3.37
$3.56
1주일 범위
$3.045
$3.56
52주 변동 폭
$1.60
$6.55
사나 바이오테크놀로지 Stock (SANA) Company Profile
명칭
Sana Biotechnology Inc
전화
(206) 701-7914
주소
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.49 | 942.27M | 0 | -244.17M | -144.77M | -0.9763 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
사나 바이오테크놀로지 Stock (SANA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-24 | 개시 | Wedbush | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-03-18 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | 개시 | Jefferies | Buy |
| 2025-01-08 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-11-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | 개시 | Rodman & Renshaw | Buy |
| 2024-01-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | 개시 | JMP Securities | Mkt Outperform |
| 2023-09-05 | 개시 | Citigroup | Buy |
| 2023-08-14 | 개시 | TD Cowen | Market Perform |
| 2023-05-02 | 개시 | H.C. Wainwright | Neutral |
| 2021-03-01 | 개시 | BofA Securities | Buy |
| 2021-03-01 | 개시 | Goldman | Neutral |
| 2021-03-01 | 개시 | JP Morgan | Neutral |
| 2021-03-01 | 개시 | Morgan Stanley | Overweight |
모두보기
사나 바이오테크놀로지 주식(SANA)의 최신 뉴스
Sana CEO Steve Harr to give business update in May 12 webcast - Stock Titan
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference - The Globe and Mail
MSN Money - MSN
SANA stock rallies 24% after hours — how much is Mayo Clinic investing in the company? - MSN
Sana Biotechnology (NASDAQ:SANA) Shares Down 7.3%Time to Sell? - MarketBeat
Sana Biotechnology abstract accepted for presentation at ASGCT By Investing.com - Investing.com India
Sana Biotechnology to present preclinical CAR-T data at May meeting - Investing.com
Sana Biotechnology abstract accepted for presentation at ASGCT - Investing.com
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting - ChartMill
Sana Biotech surges as Eric Jackson calls it a 100-bagger - MSN
Sana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 Diabetes - Yahoo Finance
Sana Biotech rises as Mayo Clinic partners for diabetes therapy - MSN
Sana Biotech Stock Jumps A Whopping 35% After Eric Jackson Calls It ‘Next 100-Bagger Platform’ - MSN
Wall Street Zen Downgrades Sana Biotechnology (NASDAQ:SANA) to Strong Sell - MarketBeat
Sana Biotechnology, Inc. ($SANA) President, CEO, and Director 2025 Pay Revealed - Quiver Quantitative
Sana Biotechnology, Inc. Files Form 8-K Current Report with SEC – Key Company Information and Details - Minichart
Sana Biotechnology | DEFA14A: Others - Moomoo
Sana Biotechnology reclassifies board member to balance director classes By Investing.com - Investing.com Australia
Sana Biotechnology Rebalances Board Classes With Director Shift - TipRanks
Sana Biotechnology reclassifies board member to balance director classes - Investing.com UK
Sana Biotechnology | DEF 14A: Definitive information statements - Moomoo
Sana Biotechnology (SANA) details 2026 virtual meeting, board elections and EY ratification - Stock Titan
Sana Biotechnology (SANA) Is Up 6.3% After Mayo-Backed SC451 Diabetes Cell Therapy CollaborationWhat's Changed - Sahm
Assessing Sana Biotechnology (SANA) Valuation After Mayo Clinic Partnership And Equity Investment - Yahoo Finance
Sana Biotechnology (SANA) Trading Range | Q4 2025: Earnings Fall ShortCommunity Sell Signals - Cổng thông tin điện tử Tỉnh Sơn La
Sana Biotechnology (SANA) Stock Stock Dividend (Grinds Lower) 2026-04-22Popular Trader Picks - Cổng thông tin điện tử tỉnh Lào Cai
Sana Biotechnology (SANA) Valuation Check After Mayo Clinic SC451 Collaboration And Recent Share Price Swing - Sahm
Sana Biotechnology Partners with Mayo Clinic for Diabetes Research - HarianBasis.co
Sana Biotechnology | 8-K: Current report - Moomoo
Wedbush Lifts PT on Sana Biotechnology (SANA) to $7 From $6 - Insider Monkey
Sana Biotechnology (NASDAQ:SANA) Stock Price Up 8.7%What's Next? - MarketBeat
10 Stocks Under $5 with Huge Upside Potential - Insider Monkey
Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
SANA Should I Buy - Intellectia AI
Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race - Benzinga
사나 바이오테크놀로지 (SANA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
사나 바이오테크놀로지 주식 (SANA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Harr Steve | President & CEO |
Mar 06 '26 |
Option Exercise |
0.00 |
41,666 |
0 |
7,918,596 |
| Wyrick Susan D. | See Remarks |
Mar 07 '26 |
Option Exercise |
0.00 |
3,250 |
0 |
200,583 |
| Wyrick Susan D. | See Remarks |
Mar 06 '26 |
Option Exercise |
0.00 |
10,416 |
0 |
197,333 |
| Wyrick Susan D. | See Remarks |
Mar 02 '26 |
Option Exercise |
0.00 |
1,525 |
0 |
187,408 |
| Wyrick Susan D. | See Remarks |
Jan 02 '26 |
Option Exercise |
0.00 |
7,500 |
0 |
188,290 |
| Wyrick Susan D. | See Remarks |
Dec 13 '25 |
Option Exercise |
0.00 |
3,400 |
0 |
181,663 |
| Wyrick Susan D. | See Remarks |
Dec 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
180,828 |
| Wyrick Susan D. | See Remarks |
Jun 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
170,395 |
0.14%
0.48%
자본화:
|
볼륨(24시간):